Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Cocks

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Epilepsy & Behavior : E&B|April 11, 2021
Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanelAndrew Trigg, Elaine Brohan, Kim Cocks, et al.
BMC Health Services Research|November 30, 2016
The patient reporting and action for a safe environment (PRASE) intervention: a feasibility studyJane K O'Hara, Rebecca J Lawton, Gerry Armitage, et al.
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
Future Oncology (London, England)|July 21, 2021
Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)Andrew Trigg, Masami Kelly, Laura Iadeluca, et al.
BMJ Quality & Safety|February 5, 2017
Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) interventionRebecca Lawton, Jane Kathryn O'Hara, Laura Sheard, et al.
Lung Cancer (Amsterdam, Netherlands)|May 23, 2022
Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72]Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, et al.
BMJ Open|August 3, 2018
Randomised controlled feasibility trial of the Active Communication Education programme plus hearing aid provision versus hearing aid provision alone (ACE to HEAR): a study protocolNicholas J Thyer, Jude Watson, Cath Jackson, et al.
Lung Cancer (Amsterdam, Netherlands)|April 12, 2022
Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trialsMichael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, et al.
BMC Cancer|October 8, 2021
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trialsEva M Gamper, Jammbe Z Musoro, Corneel Coens, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2018
Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanomaJammbe Z Musoro, Andrew Bottomley, Corneel Coens, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Epilepsy & Behavior : E&B|April 11, 2021
Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanelAndrew Trigg, Elaine Brohan, Kim Cocks, et al.
BMC Health Services Research|November 30, 2016
The patient reporting and action for a safe environment (PRASE) intervention: a feasibility studyJane K O'Hara, Rebecca J Lawton, Gerry Armitage, et al.
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
Future Oncology (London, England)|July 21, 2021
Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)Andrew Trigg, Masami Kelly, Laura Iadeluca, et al.
BMJ Quality & Safety|February 5, 2017
Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) interventionRebecca Lawton, Jane Kathryn O'Hara, Laura Sheard, et al.
Lung Cancer (Amsterdam, Netherlands)|May 23, 2022
Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72]Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, et al.
BMJ Open|August 3, 2018
Randomised controlled feasibility trial of the Active Communication Education programme plus hearing aid provision versus hearing aid provision alone (ACE to HEAR): a study protocolNicholas J Thyer, Jude Watson, Cath Jackson, et al.
Lung Cancer (Amsterdam, Netherlands)|April 12, 2022
Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trialsMichael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, et al.
BMC Cancer|October 8, 2021
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trialsEva M Gamper, Jammbe Z Musoro, Corneel Coens, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2018
Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanomaJammbe Z Musoro, Andrew Bottomley, Corneel Coens, et al.
Pageof 9